The Food and Drug Administration recently authorized the temporary import of hydromorphone hydrochloride injection from Canada to address a critical shortage of the drug, an opioid pain medication. This product is marketed in Canada, and is manufactured in Canada by Sandoz Canada Inc. At this time, no other entity except Hospira is authorized by the FDA to import or distribute Sandoz Hydromorphone Hydrochloride Injection, USP 2 mg/mL ampules in the U.S. See the letter to health care providers for more details. 

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
The AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical…
Headline
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…
Headline
Public and private entities can apply for $1 million grants for a three-year period to enhance or expand opioid and other substance use disorder services in…